Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Looks To Build U.S. Injectables Business Through Sabex Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will add Infufer and hydromorphone injectables in the U.S. following $565 mil. transaction. Sabex makes 89 generic molecules for the Canadian market in its FDA-approved facilities.

You may also be interested in...



Novartis Buys Ebewe’s Injectable Cancer Drug Business

The €925 million deal provides Novartis’ Sandoz division with a fast-growing generic oncology business and expanded development portfolio.

Novartis Buys Ebewe’s Injectable Cancer Drug Business

The €925 million deal provides Novartis’ Sandoz division with a fast-growing generic oncology business and expanded development portfolio.

Novartis' Generics Acquisition Strategy Aims To Add Products, Not Size

Novartis' acquisition strategy for its generics business aims to strengthen Sandoz' negotiating capability with chain pharmacies by adding products to its portfolio rather than simply increasing the business' scale.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel